0001493152-23-030303.txt : 20230828 0001493152-23-030303.hdr.sgml : 20230828 20230828081017 ACCESSION NUMBER: 0001493152-23-030303 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230828 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230828 DATE AS OF CHANGE: 20230828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMERICA INC CENTRAL INDEX KEY: 0000073290 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952645573 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37863 FILM NUMBER: 231210346 BUSINESS ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9493792875 MAIL ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: NMS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19871130 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19830216 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR INSTRUMENTS INC DATE OF NAME CHANGE: 19720508 8-K 1 form8-k.htm
0000073290 false 0000073290 2023-08-28 2023-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 28, 2023

 

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37863   95-2645573

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

17571 Von Karman Ave. Irvine, California   92614
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (949) 645-2111 

 

Not Applicable

(Former name or former address if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.08   BMRA   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective August 25, 2023, the board of directors (the “Board”) of Biomerica, Inc. (the “Company”) expanded the size of the Board by one member and elected and appointed Mr. Jack Kenny to serve as an independent member of the Board effective immediately.

 

The Board has determined that Mr. Kenny is an independent director within the meaning of NASDAQ Rule 5605. In addition to his appointment as an independent director, Mr. Kenny will serve as the Chairperson of the Board’s Nominating and Corporate Governance Committee and shall also serve as a member of the Audit Committee.

 

In connection with Mr. Kenny’s appointment to the Board, Mr. Kenny will receive an annualized cash fee of $52,500 (paid quarterly), and other equity-based compensation that shall be determined at a later date.

 

Mr. Kenny does not have a family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Kenny and any other persons pursuant to which he was selected as a director, and there are no transactions in which he has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

On August 28, 2023, the Company issued a press release announcing the appointment of Mr. Kenny as a director of the Board, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1   Press Release issued August 28, 2023
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOMERICA, INC.
     
Date: August 28, 2023 By: /s/ Zackary S. Irani
    Zackary S. Irani Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

NEWS- For Immediate Release

 

Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors

 

  - Kenny has a proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian Bioscience

 

  - As CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion

 

NEWPORT BEACH, CA – August 28, 2023 – Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leading global provider of diagnostic testing solutions. Meridian Biosciences was acquired on January 31, 2023 by SD Biosensor, Inc. and SJL Partners LLC in an all-cash transaction valued at approximately $1.53 billion.

 

“I’m excited to join Biomerica’s Board and contribute to the launch and growth of the company’s groundbreaking product, inFoods® IBS. This product holds the potential to not only significantly improve the lives of millions of individuals dealing with IBS but also capture the interest of larger multinational diagnostic companies. The technology’s appeal extends beyond its ability to enhance patient well-being, as it also stands to reduce healthcare costs and equip physicians with a precise, personalized approach to treating IBS.

 

The compelling clinical study data supporting inFoods® IBS has underscored its potential to deliver therapeutic benefits for IBS patients. As I take on my role within Biomerica’s board, I’m eagerly looking forward to close collaboration with the management team. Together, we’ll strive to introduce this remarkable technology to medical professionals and patients around the world with the goal of improving healthcare outcomes while driving down costs for patients and insurers,” said Mr. Kenny.

 

“Jack brings a wealth of commercial experience and relationships in the medical diagnostic industry. His industry insights will be invaluable as we launch inFoods® IBS both domestically and internationally,” said Zack Irani, CEO of Biomerica. “Jack brings more than 30 years of experience as a senior executive at large public companies in the healthcare, clinical laboratory and medical device industries. Most recently, his leadership as CEO drove outstanding growth at Meridian Bioscience. Jack also brings strong public company governance experience that will facilitate corporate oversite as our business expands and grows.”

 

Prior to his role as CEO at Meridian, Mr. Kenny was the Senior Vice President and General Manager, North America at Siemens Healthcare, and before that was Vice President and General Manager, U.S. Region for Diagnostic Systems at Becton Dickinson. Throughout his career, Mr. Kenny has held additional leadership positions of increasing responsibility including key roles at Leica Microsystems, Quest Diagnostics and Bayer Diagnostics. He holds a Bachelor of Science in management systems from Kettering University in Michigan.

 

About inFoods® IBS:

 

The inFoods® IBS test involves a simple blood collection procedure and is designed to assess a patient’s above normal immunoreactivity to specific foods. Instead of difficult to manage broad dietary restrictions, physicians can now use the inFoods® IBS information to make targeted, patient-specific recommendations about specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Further information about Biomerica’s patented inFoods® Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/. It is estimated that over 40 million Americans suffer from IBS, with symptoms often triggered by consumption of specific foods (which are unique to each patient). The total direct and indirect cost of IBS has been estimated at $30 billion annually in the United States alone.

 

 

 

 

NEWS- For Immediate Release

 

About Biomerica (NASDAQ: BMRA)

 

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s inFoods® IBS test and other tests, FDA clearance or possible future clearance of the Company’s inFoods® IBS test and other products, timing of the commercial launch of the inFoods® IBS test, the efficacy of the inFoods product, possible future revenues from the sale of the inFoods® IBS test, growth in future revenues from the sale of the inFoods® IBS test, acceptance of the inFoods® IBS test by physicians and their patients, international regulatory approval and sales of the inFoods® IBS test, accuracy, efficacy and clinical trial results of the inFoods® IBS test, the rapidity of testing results, negotiations with clinical labs who would offer the inFoods® IBS test, the ability of a CLIA-certified, high-complexity lab to offer the inFoods® IBS test as a laboratory developed test (LDT), discussions with physicians and physician groups who could or would offer the inFoods Test to their patients, efficacy of the inFoods IBS test to improve IBS symptoms in patients, the company’s ability to manufacture the inFoods® IBS test as a commercial product and to increase manufacturing capacity to meet future product demands, any future FDA marketing authorization, the uniqueness of the Company’s inFoods® IBS test and other products, pricing of the Company’s inFoods® IBS test, future possible insurer reimbursement for the inFoods® IBS test, patent protection on the inFoods® IBS and the underlying technology of the test, or on any of the Company’s other products or technologies, and current or future competition for the inFoods® IBS test from other medical manufacturers or distributors. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests and products; regulatory approvals necessary prior to commercialization any of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

 

Corporate Contact:

 

Zack Irani-Cohen

949-645-2111

investors@biomerica.com

 

Source: Biomerica, Inc.

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 bmra-20230828.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 bmra-20230828_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 bmra-20230828_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 28, 2023
Entity File Number 001-37863
Entity Registrant Name BIOMERICA, INC.
Entity Central Index Key 0000073290
Entity Tax Identification Number 95-2645573
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 17571 Von Karman Ave
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92614
City Area Code 949
Local Phone Number 645-2111
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.08
Trading Symbol BMRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000073290 2023-08-28 2023-08-28 iso4217:USD shares iso4217:USD shares 0000073290 false 8-K 2023-08-28 BIOMERICA, INC. DE 001-37863 95-2645573 17571 Von Karman Ave Irvine CA 92614 949 645-2111 false false false false Common Stock, par value $0.08 BMRA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4L0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !(01Q7 M)!Z;HJT #X 0 &@ @ &K$0 >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " !(01Q799!YDAD! #/ P $P M @ &0$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( #:$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biomerica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm bmra-20230828.xsd bmra-20230828_lab.xml bmra-20230828_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "bmra-20230828_lab.xml" ] }, "presentationLink": { "local": [ "bmra-20230828_pre.xml" ] }, "schema": { "local": [ "bmra-20230828.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bmra", "nsuri": "http://biomerica.com/20230828", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biomerica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biomerica.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-030303-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-030303-xbrl.zip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